Abraham Michael Lincoff, MD, FACC
Professor Emeritus of Medicine
Cleveland Clinic Foundation

Printed as of 11/17/2026

Disclosures

Personal Commercial (13)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
AbbVie, Inc.	Research/Research Grants *‡ Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study*	Significant (>= $5,000)	*General Cardiology*
Alnylam	Consultant Fees/Honoraria	Significant (>= $5,000)	*Other*
Amgen Inc.	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
Canary Cure	Stock	Significant (>= $5,000)	*Prevention*
Eli Lilly and Company	Consultant Fees/Honoraria	Significant (>= $5,000)	*Prevention*
Esperion	Research/Research Grants *‡ CLEAR Outcomes - Effects of Bempedoic Acid (ETC 1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at high risk for, Cardiovascular Disease who are Statin Intolerant*	Significant (>= $5,000)	*Prevention*
Medscape	Consultant Fees/Honoraria	Modest (< $5,000)	*General Cardiology*
Medtronic	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Novartis	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Novo Nordisk	Consultant Fees/Honoraria	Significant (>= $5,000)	*Prevention*
ReCor	Consultant Fees/Honoraria	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
v-wave	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/24/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/24/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 9/24/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 9/24/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.